Avidity Biosciences, Inc. RNA
Updated: 12 Aug 2026
No signal published yet
We already track Avidity Biosciences and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Avidity Biosciences, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Avidity Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In February 2026, Novartis completed its acquisition of Avidity Biosciences for approximately $12 billion, making the company a wholly owned subsidiary. Prior to the transaction's close, Avidity spun off its early-stage precision cardiology programs into Atrium Therapeutics, Inc.
What Firelda Watch includes for Avidity Biosciences, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Avidity Biosciences, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Avidity Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more